The U.S. Food and Drug Administration approved Adamas Pharmaceuticals' Gocovri for treating a side effect caused by a popular Parkinson’s drug, according to a Reuters article. As a result, the company’s shares jumped 30.9 percent.
Many patients who struggle with Parkinson’s are treated with levodopa, but that often leads to dyskinesia, causing involuntary movements that are non-rhythmic, purposeless and unpredictable.
Gocovri, previously called ADS-5102, is said to be the first drug approved by the FDA to control levodopa-induced dyskinesia (LID).
Read the full story